関連する実験動画
Updated: Jul 5, 2026

10:10
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
エピネフリンは,ヴォン・ウィレブランド因子に依存した切断誘発性血小板凝集を増加させる
1Cardiopulmonary Division, School of Medicine, Keio University, Tokyo, Japan.
Circulation
|December 1, 1992
まとめ
エピネフリンは,高シア条件下でフォン・ウィレブランド因子 (vWF) を介してシア誘発性血小板凝集 (SIPA) を強化します. この相互作用は,狭窄した動脈における血栓形成を理解するために重要である.
科学分野:
- 血液学 ヘマトロジ
- バイオフィジックス 生物物理学
背景:
- シーア誘発性血小板結束 (SIPA) は,血栓形成 (血栓形成) の重要な要因である.
- フォン・ウィレブランド因子 (vWF) が血小板グリコプロテインIb (GP Ib) に結合することは,動脈の狭窄に見られるような高い切断力下での血小板集積に不可欠です.
研究 の 目的:
- vWFに依存するSIPAの生理学的意義を明確にするために.
- SIPAにおけるエピネフリン,ADP,およびコラーゲンのようなアゴニストの役割を,異なる剪定条件下で調査する.
主な方法:
- 23人の健康なボランティアの血液サンプルを分析した.
- SIPAは,光伝導を測定する改造された円板粘度計を使用して監視されました.
- エピネフリン,ADP,およびコラーゲンのSIPAへの影響は,低い (12ダイネ/cm2) および高い (108ダイネ/cm2) 切断力でテストされました.
主要な成果:
- エピネフリン,ADP,およびコラーゲンは,低シアでSIPAを強化しました.
- エピネフリンのみが,高シアでSIPAを補強し,アグレゲーションを37.9%から59.7%に増加させた.
- アルファ2アドレナリゲン受容体アンタゴニスト (ヨーヒンビン) はエピネフリンの効果を阻害し,抗vWF抗体 (NMC-4) は高シアSIPAを廃止した.
結論:
- エピネフリンは,その特定の受容体を通してvWF媒介のSIPAを強化する主要なアゴニストとして作用します.
- このメカニズムは,交感性刺激中に動脈硬化血管で冠動脈閉塞がしばしば起こるため,臨床的に重要である.
関連する概念動画
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

